Should UACR 42 mg/g Be Repeated Annually?
Yes, repeat the UACR annually, but also confirm the diagnosis first with a second test within 3-6 months if this is the initial abnormal result. 1
Initial Confirmation Required
A UACR of 42 mg/g falls into the moderately increased albuminuria category (30-299 mg/g), previously called microalbuminuria 1, 2. Before establishing this as a persistent finding:
- Confirm with 2 of 3 tests positive within 3-6 months to establish persistent albuminuria 2, 3
- This accounts for the 40-50% day-to-day variability in albumin excretion 2, 4
- However, recent evidence shows a single abnormal UACR (2-20 mg/mmol, roughly equivalent to 18-180 mg/g) has a 96.8% positive predictive value for persistent disease 5, suggesting confirmation may be less critical than traditionally thought
Annual Monitoring After Diagnosis
Once moderately increased albuminuria is confirmed:
- Screen annually with spot UACR 1, 2
- This applies to all adults with diabetes regardless of treatment status 1
- Annual testing helps assess disease progression and treatment response 2
More Frequent Monitoring Situations
Increase monitoring to every 6 months if: 2
- eGFR is <60 mL/min/1.73 m²
- Patient is on treatment for albuminuria (to assess therapeutic response)
- You need to determine if therapy is effectively reducing albuminuria
Treatment Implications at UACR 42 mg/g
With confirmed moderately increased albuminuria:
- Start an ACE inhibitor or ARB (Level B recommendation) 1
- Optimize blood pressure to <130/80 mmHg 1
- Optimize glucose control 1
- Treatment goal: reduce UACR by at least 30-50%, ideally to <30 mg/g 2
Common Pitfalls to Avoid
- Don't rely on a single test for initial diagnosis if following traditional guidelines, though newer evidence suggests this may be acceptable 5
- Avoid testing after vigorous exercise within 24 hours 3
- Use first morning void when possible to minimize variability 2, 6
- Don't forget to monitor eGFR simultaneously - both are required for complete CKD staging 1
- Remember that UACR variability is high (coefficient of variation ~49%) 4, so interpret changes cautiously
The 2024 ADA guidelines provide the most current framework: annual screening is standard, with more frequent monitoring (1-4 times yearly) based on CKD stage and treatment status 1.